Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Medicenna Therapeutics Corp
T.MDNA
Alternate Symbol(s):
MDNAF
Healthcare
Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior...
CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:MDNA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Next
(98)
•••
windymayor1
X
View Profile
View Bullboard History
Post by
windymayor1
on Jan 26, 2022 2:24pm
PR
Good News. Not sure what the market is waiting for ?!
(1898)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Jan 26, 2022 8:55am
Peer-Reviewed Publication of Preclinical Data on MDNA11
MDNA11 demonstrates a 30-fold increase in affinity for IL-2 receptor beta without binding to IL-2 receptor alpha when compared to recombinant human IL-2 -- MDNA11 was well-tolerated and induced
...more
CLOUD DX Signs Multi-Year Contract with Provincial Health Authority
posted May 07, 2024 9:00am by
Cloud DX Inc.
-
|
The company is pleased to announce the execution on April 23, 2024 of a Remote Patient Monitoring Agreement for Cloud DX RPM Services with a Canadian Provincial Health Authority. This agreement is the 4th Provincial Health Authority contract for Cloud DX remote patient monitoring (RPM) services, alongside Alberta, the Yukon and Prince Edward Island. The contract has a term of 36 months with 2 extensions of 12 months each. The average contract value of each individual subscription is expected to be approximately ...read more
(0)
•••
HarryGluten
X
View Profile
View Bullboard History
Post by
HarryGluten
on Nov 17, 2021 8:04am
mdna 52 week high very possible, very soon
$mdna 52 week high of $6.82. If it was done once, it can be done again, esp with big catalyst in less than one month!
(0)
•••
HarryGluten
X
View Profile
View Bullboard History
Post by
HarryGluten
on Nov 17, 2021 6:45am
mdna 55 deal
This would be huge: Resesarch Capital Analyst Uddin believes efforts to secure deal for $MDNA 55 prior to start of Phase 3 clinical trial will serve as key catalyst, as he made the assumption of a
...more
(0)
•••
HarryGluten
X
View Profile
View Bullboard History
Post by
HarryGluten
on Nov 17, 2021 6:42am
Research Capital price target of $6.90
$mdna Canadian biotech company Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News TSX:MDNA) has lost a lot of ground in 2021 but analyst Andre Uddin of Research Capital
...more
(0)
•••
HarryGluten
X
View Profile
View Bullboard History
Post by
HarryGluten
on Nov 16, 2021 10:51am
MDNA is a swing trade now! let's go!
$mdna big swing trading play... mdna will report data on their lead drug program (mdna 11) in December 2022! Stock will continue to rally into December, and if results are good, I agree with zack'
...more
(0)
•••
HarryGluten
X
View Profile
View Bullboard History
Post by
HarryGluten
on Nov 16, 2021 7:20am
Third site goes up for MDNA 11 clinical trials
$mdna third clinical site for mdna 11 is now recruiting in Victoria, Australia https://clinicaltrials.gov/ct2/show/NCT05086692#contacts
(0)
•••
HarryGluten
X
View Profile
View Bullboard History
Post by
HarryGluten
on Nov 15, 2021 10:33am
MDNA stifel conference today
$mdna at Stifel conference presentation - Expect to present mdna 11 efficacy data at ASCO June 3, 2022 - MDNA 55 discussions still active and ongoing with several
...more
(0)
•••
HarryGluten
X
View Profile
View Bullboard History
Post by
HarryGluten
on Nov 13, 2021 7:01am
MDNA reports earnings / good progress on MDNA 11
$mdna December setting up to be huge month of catalysts! Pivotal month. PK/PD for mdna 11 in late December. Assuming that goes well, we will be off to the races as investors build positions for 2022.
...more
(0)
•••
HarryGluten
X
View Profile
View Bullboard History
Post by
HarryGluten
on Nov 13, 2021 7:00am
MDNA recent seeking alpha article
Good seeking alpha article summarzing $MDNA opportunity... end of 2021 and year 2022 looking very good for this little stock that could...multi-bagger potential within a year... good time to buy
...more
(0)
•••
HarryGluten
X
View Profile
View Bullboard History
Post by
HarryGluten
on Nov 13, 2021 7:00am
MDNA CEO insider buying
$MDNA CEO Merchant bought $100K of shares open market recently, avg price $2.15. CFO added a few shares too. Merchant already largest shareholder at 30%+,continues toadd. This is very positive given 9
...more
(0)
•••
HarryGluten
X
View Profile
View Bullboard History
Post by
HarryGluten
on Nov 06, 2021 10:02am
MDNA tax loss selling pressure
According to Canaccord : in last 5 years, stocks on TSX down more than 15% ytd as of mid-Nov have underperformed the index by almost 4% over the month to mid-Dec and then, in the subsequent month (mid
...more
(0)
•••
HarryGluten
X
View Profile
View Bullboard History
Post by
HarryGluten
on Nov 05, 2021 10:37am
MDNA competitor NKTR reported earnings
nktr reported earnings yesterday. Stock down 20%+ as market not liking some early data results from ph1/ph2 keytruda combo + their main drug IL-2 BEMPEG NKTR 214 for lung cancer (propel); recall that
...more
(0)
•••
HarryGluten
X
View Profile
View Bullboard History
Post by
HarryGluten
on Oct 28, 2021 7:33am
mdna added new trial sites
$mdna Updated: 10/27/2021 3 additional sites have been added in Australia. Can go to clinical .gov site Medicenna ability study https://clinicaltrials.gov/ct2/show
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Multiple High-Grade Gold Hits at the Tonopah Gold Project Including 90 Meters at 2.0 gpt Gold
Meet one of the Strongest Contenders to Lead Canada’s Cannabis Market
A Leading Provider in Virtual Healthcare Adds 4th Provincial Health Authority Contract
NOI Filed for Drill Program at Lithium/Uranium Project in Nevada
Silvercorp to Acquire Adventus for Implied Consideration of C$0.50 per Share